Global Drugs For Benign Prostatic Hypertrophy Market Potential Growth, Share, Demand and Analysis of Key Players & Forecasts to 2032 | Allergan PLC., Astellas Pharma Inc., Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline PLC.

The Business Research Company's global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

As per the Drugs For Benign Prostatic Hypertrophy market report by The Business Research Company, The rising male geriatric population globally is driving the market for Benign Prostatic Hypertrophy drugs as the condition is commonly seen in men aged over 50 years. According to the United Nations' 2019 World Population Ageing Report, the number of people aged 65 years or above was 703 million in 2019 and is expected to double to around 1.5 billion by 2050. According to the National Institute of Health (NIH), Benign Prostatic Hyperplasia affects around 50% of men aged between 51 and 60 years and up to 90% of men aged over 80 years.

The global drugs for benign prostatic hypertrophy market size will grow from $6.45 billion in 2022 to $6.86 billion in 2023 at a compound annual growth rate (CAGR) of 6.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global drugs for benign prostatic hypertrophy market size is expected to grow to $8.18 billion in 2027 at a CAGR of 4.5%.

Read More On The Drugs For Benign Prostatic Hypertrophy Market Report Here:
https://www.thebusinessresearchcompany.com/report/drugs-for-benign-prostatic-hypertrophy-global-market-report

Major competitors in the Drugs For Benign Prostatic Hypertrophy market include Allergan PLC., Astellas Pharma Inc., Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline PLC., Teva Pharmaceutical Industries Limited, Sanofi, Nymox Pharmaceutical Corporation, and AEternaZentaris Inc.

The Drugs For Benign Prostatic Hypertrophy market is segmented -

•By Type: Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types
•By End User: Hospital Pharmacies, Retail Pharmacies, Other End-Users
•By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies. North America was the largest region in the drugs for benign prostatic hypertrophy market in 2022.
Request A Free Sample Of The Drugs For Benign

Prostatic Hypertrophy Market Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2594&type=smp

The drug benign prostatic hypertrophy refers to benign prostatic hypertrophy drugs that are used to treat enlarged prostate glands by relaxing bladder neck muscles and muscle fibres in the prostate, making urination easier. Benign Prostatic Hypertrophy is commonly seen in men older than 50.
The main types of drugs for benign prostatic hypertrophy are alpha-blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and others.

The Table Of Content For The Drugs For Benign Prostatic Hypertrophy Market Include:

1. Executive Summary
2. Drugs For Benign Prostatic hypertrophy Market Characteristics
3. Drugs For Benign Prostatic hypertrophy Market Trends And Strategies
4. Drugs For Benign Prostatic hypertrophy Market - Macro Economic Scenario
5. Drugs For Benign Prostatic hypertrophy Market Size And Growth
……
27. Drugs For Benign Prostatic hypertrophy Market Competitive Landscape And Company Profiles
28. Drugs For Benign Prostatic hypertrophy Pipeline Analysis
29. Key Mergers And Acquisitions In The Drugs For Benign Prostatic hypertrophy Market
30. Drugs For Benign Prostatic hypertrophy Market Future Outlook and Potential Analysis
31. Appendix

The "Global Drugs For Benign Prostatic Hypertrophy Market Report 2023" from The Business Research Company is a comprehensive report that covers every facet of a market covering over 60 geographies and over 2500 market segments. The regional and country breakdowns section analyzes the market in each geography and the market size by region and country. Furthermore, it assesses the market's historical and projected growth and identifies significant trends and strategies that companies can leverage for business expansion.

Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

This release was published on openPR.